EGFR and non-small cell lung carcinoma: Yang's [17] study which was based on a pooled analysis of the LUX‐Lung 2, LUX‐Lung 3, and LUX‐Lung 6 clinical trialss reported that afatinib was effective in 75 NSCLC patients harboring uncommon EGFR mutations, with an ORR of 41.3%, a mPFS of 10.7 months and a mOS of 19.4 months.